Autoimmune diseases: MIF as a therapeutic target

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 3, 2010, Pages 253-264

  Greven, Dorothee ^a   Leng, Lin ^b   Bucala, Richard ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b YALE UNIVERSITY   (United States)

Author keywords

Autoimmunity; Cytokine; MIF alleles; Rheumatoid arthritis; SLE

Indexed keywords

ANTIBODY; CORTICOTROPIN; GLUCOCORTICOID; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ALLERGIC NEUROPATHY; AMINO TERMINAL SEQUENCE; ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; BINDING SITE; CELL SURVIVAL; CHROMOSOME 22; DIABETES MELLITUS; ENTERITIS; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; GIANT CELL ARTERITIS; GLOMERULONEPHRITIS; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; MULTIPLE SCLEROSIS; NONHUMAN; POLYARTERITIS NODOSA; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; UVEITIS; WEGENER GRANULOMATOSIS;

ANIMALS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; GENOTYPE; GLUCOCORTICOIDS; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS;

EID: 77149175945     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903551304     Document Type: Review

References (100)

1. Janeway C. Autoimmunity and transplantation. In: Janeway C, Travers P, Walport M, Shlomchik M, editors, Immunobiology, Garland, New York, NY; 2005. p. 557-612
2. Bucala R, Lolis E. MIF: a critical component of autoimmune inflammatory diseases. Drug News Perspect 2005;18(7):417-426
3. Feldmann M, Maini RN. Anti-TNFalpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-196
4. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19(1):12-19
5. Andreakos ET, Foxwell BM, Brennan FM, et al. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor 2002;13(4-5):299-313
6. Waldner H. The role of innate immune responses in autoimmune disease development. Autoimmun Rev 2009;8(5):400-404
7. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993;328:106-113
8. Feldmann M, Brennan FM, Paleolog E, et al. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Novartis Found Symp 2004;256:53-69
9. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003;3:791-800 (Pubitemid 37328657)
10. Lolis E, Bucala R. Macrophage migration inhibitory factor. Expert Opin Ther Targets 2003;7:153-164
11. Bozza M, Satoskar AR, Lin G, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999;189:341-346
12. Mitchell RA, Liao H, Chesney J, et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 2002;99:345-350
13. Bernhagen J, Calandra T, Mitchell RA, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993;365:756-759 (Pubitemid 23339882)
14. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994;179:1895-1902 (Pubitemid 24155670)
15. Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:68-71
16. Donnelly SC, Haslett C, Reid PT, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 1997;3:320-323
17. Daun JM, Cannon JG. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IkBalpha. Am J Physiol 2000;279:R1043-9
18. Wang L, Das H, Kamath A, et al. Human Vgamma2Vdelta2 T cells augment MIF secretion and counteract the inhibitory effect of glucocorticoids on IL-1beta and TNF-alpha production. J Immunol 2002;168:4889-4896
19. Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999;274:18100-18106
20. Flaster H, Bernhagen J, Calandra T, Bucala R. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 2007;21(6):1267-1280 (Pubitemid 46984737)
21. Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 2005;35(12):3405-3413
22. Aeberli D, Yang Y, Mansell A, et al. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBBS Lett 2006;580(3):974-980
23. Leng L, Wang W, Roger T, et al. Glucocorticoid-induced MIF expression by human CEM T cells. Cytokine 2009;48(3):177-185
24. Bacher M, Meinhardt A, Lan HY, et al. Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 1997;150:235-246
25. Fingerle-Rowson G, Koch P, Bikoff R, et al. Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol 2003;162:47-56 (Pubitemid 36041989)
26. Suzuki M, Sugimoto H, Nakagawa A, et al. Crystal structure of the macrophage migration inhibitory factor from rat liver. Nat Struct Biol 1996;3:259-266
27. Sun HW, Bernhagen J, Bucala R, Lolis E. Crystal structure at 2.6-A - resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 1996;93:5191-5196
28. Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-1476
29. Kleemann R, Hausser A, Geiger G, et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000;408:211-216
30. Hudson JD, Shoaibi MA, Maestro R, et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999;190:1375-1382
31. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007;13:587-596
32. Weber C, Kraemer S, Drechsler M, et al. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci USA 2008;105(42):16278-16283
33. Bacher M, Metz CN, Calandra T, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996;93:7849-7854 (Pubitemid 26277127)
34. Bernhagen J, Bacher M, Calandra T, et al. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med 1996;183:277-282 (Pubitemid 26028767)
35. Abe R, Peng T, Sailors J, et al. Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol 2001;166:747-753
36. Denkinger CM, Denkinger M, Kort JJ, et al. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol 2003;170:1274-1282
37. Mikulowska A, Metz CN, Bucala R, Holmdahl R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol 1997;158:5514-5517
38. de JongYP, Abadia-Molina AC, Satoskar AR, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001;2:1061-1066
39. Nishihira J, Ogata A. Macrophage migration inhibitory factor as a target molecule in multiple sclerosis. Curr Opin Invest Drugs 2001;2:778-782 (Pubitemid 32936670)
40. Leech M, Metz C, Santos L, et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 1998;41:910-917 (Pubitemid 28225792)
41. Ichiyama H, Onodera S, Nishihira J, et al. Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF). Cytokine 2004;26:187-194
42. Leech M, Metz C, Hall P, et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999;42:1601-1608
43. Morand EF. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J 2005;35:419-426
44. Morand EF, Leech M, Weedon H, et al. Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology 2002;41(5):558-562
45. Tanasescu C, Jurcut C, Jurcut R, Ginghina C. Vascular disease in rheumatoid arthritis: from subclinical lesion to cardiovascular risk. Eur J Intern Med 2009;20(4):348-354
46. Atsumi T, Cho YR, Leng L, et al. The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. J Immunol 2007;179(8):5399-5406
47. Chen Z, Sakuma M, Zago AC, et al. Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol 2007;24(4):709-714
48. Wijbrandts CA, van Leuven SI, Boom HD, et al. Sustained changes in lipid profile and macrophage migration inhibitory factor (MIF) levels after anti-TNF therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68(8):1316-1321
49. Nishihira J, Mitsuyama K. Overview of the role of macrophage migration inhibitory factor in inflammatory bowel disease. Curr Pharm Des 2009;15(18):2104-2109
50. Kitaichi N, Kotake S, Mizue Y, et al. Increase of macrophage migration inhibitory factor in sera of patients with iridocyclitis. Br J Ophthalmol 2000;84:1423-1425
51. Niino M, Ogata A, Kikuchi S, et al. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J Neurol Sci 2000;179:127-131
52. Kotake S, Kitaichi N, Ohno S. Macrophage migration inhibitory factor in uveitis. Int Ophthalmol Clin 2002;42:99-103
53. Nicoletti F, Créange A, Orlikowski D, et al. Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barré syndrome and experimental allergic neuritis. J Neuroimmunol 2005;168(1-2):168- 174
54. Lan HY, Bacher M, Yang N, et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 1997;185:1455-1465
55. Lan H. Role of macrophage migration inhibitory factor in kidney disease. Nephron Exp Nephrol 2008;109:e79-83
56. Shlomchik M, Craft J, Mamula M. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Immunol 2001;1:147-153
57. Foote A, Briganti EM, Kipen Y, et al. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 2004;31:268-273
58. Hoi AY, Hickey MJ, Hall P, et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol 2006;177(8):5687-5696
59. Becker H, Maaser C, Mickholz E, et al. Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides. Clin Rheumatol 2006;25(3):368-372
60. Becker H, Willeke P, Schotte H, et al. Macrophage migration inhibitory factor may contribute to vasculopathy in systemic sclerosis. Clin Rheumatol 2008;27(10):1307-1311
61. Stosic-Gruijcic S, Stojanovic I, Maksimovic-Ivanic D, et al. Macrophage migration inhibitory factor is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol 2008;215(3):665-675
62. Bojunga J, Kusterer K, Bacher M, et al. Macrophage migration inhibitory factor and development of type-1 diabetes in non-obese diabetic mice. Cytokine 2003;21:179-186
63. Baugh JA, Chitnis S, Donnelly SC, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002;3:170-176
64. De Benedetti F, Meazza C, Vivarelli M, et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic juvenile idiopathic arthritis. Arthritis Rheum 2003;48:1398-1407
65. Donn R, Alourfi Z, Zeggini E, et al. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum 2004;50:1604-1610
66. Stosic-Gruijcic S, Stojanovic I, Nicoletti F. MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev 2009;8(3):244-249
67. Radstake TR, Sweep FC, Welsing P, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005;52:3020-3029
68. Vivarelli M, D'Urbano LE, Insalaco A, et al. Macrophage migration inhibitory factor (MIF) and oligoarticular juvenile idiopathic arthritis (o-JIA): association of MIF promoter polymorphisms with response to intra-articular glucocorticoids. Clin Exp Rheumatol 2007;25(5):775-781
69. Donn RP, Plant D, Jury F, et al. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol 2004;123:484-487
70. Donn RP, Shelley E, Ollier WE, Thomson W. A novel 5¢-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001;44:1782-1785
71. Nohara H, Okayama N, Inoue N, et al. Association of the -173G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol 2004;39:242-246
72. Dambacher J, Staudinger T, Seiderer J, et al. Macrophage migration inhibitory factor (MIF) -173G/C promotor polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. Inflamm Bowel Dis 2007;13:71-82
73. Griga T, Wilkens C, Wirkus N, et al. A polymorphism in the macrophage migration inhibitory factor gene is involved in the genetic predisposition of Crohn's disease and associated with cumulative steroid doses. Hepatogastroenterology 2007;54(75):784-786
74. Mizue Y, Ghani S, Leng L, et al. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci USA 2005;102(4):14410-14415 (Pubitemid 41429711)
75. Wu SP, Leng L, Feng Z, et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 2006;54(11):3661-3669
76. Hizawa N, Yamaguchi E, Takahashi D, et al. Functional polymorphisms in the promoter region of macrophage migration inhibitory factor and atopy. Am J Respir Crit Care Med 2004;169:1014-1018
77. Amoli M, Donn RP, Thomson W, et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 2002;29:1671-1673
78. Jawaheer D, Gregersen P. The search for rheumatoid arthritis susceptibility genes: a call for global collaboration. Arthritis Rheum 2002;46:582-584
79. Gregersen P, Bucala R. MIF, MIF alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. Arthritis Rheum 2003;48:1171-1176
80. Mcguire W, Hill AV, Allsopp CE, et al. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508-510
81. Leech M, Metz C, Bucala R, Morand EF. Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43:827-833
82. Ramanujam M, Davidson A. Targeting of the immune system in systemic lupus erythematosus. Expert Rev Mol Med 2008;10:e2. Published online 21 Jan 2008, doi: 10.1017/S1462399408000562 (Pubitemid 351338214)
83. Aringer M, Steiner G, Graninger WB, et al. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007;56(1):274-279
84. Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000;6:164-169
85. Baxter International, Inc. News & Analysis. Anti-MIF technology licensed to large pharmaceutical company. Cancer Weekly, 10 April 2003
86. Swope MD, Lolis E. Macrophage migration inhibitory factor: cytokine, hormone, or enzyme. Rev Physiol Biochem Pharmacol 1999;139:1-32
87. Rosengren E, Bucala R, Aman P, et al. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 1996;2:143-149
88. Shi X, Leng L, Wang T, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006;25(4):595-606
89. Fingerle-Rowson G, Kaleswarapu DR, Schlander C, et al. A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol Cell Biol 2009;29(7):1922-1932
90. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharm Exp Ther 2002;301:418-426
91. Senter PD, Al-Abed Y, Metz CN, et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci USA 2002;99:144-149
92. Lubetsky JB, Dios A, Han J, et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 2002;277:24976-24982
93. Cvetkovic I, Stosic-Grujicic S. Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders. Int Immunopharmacol 2006;6(10):1527-1534
94. Arjona A, Foellmer HG, Town T, et al. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest 2007;117(10):3059-3066
95. Dagia NM, Kamath DV, Bhatt P, et al. A fluorinated analog of ISO-1 blocks the recognition and biological function of MIF and is orally efficacious in a murine model of colitis. Eur J Pharmacol 2009;607(1-3):201-212
96. Cournia Z, Leng L, Gandavadi S, et al. Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem 2009;52(2):416-424
97. Orita M, Yamamoto S, Katayama N, Fujita S. Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors. Curr Pharm Res 2002;8:1297-1317
98. Winner M, Meier J, Zierow S, et al. A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res 2008;68(18):7253-7257
99. Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13(18 Pt 2):5556s-63s
100. Coleman AM, Rendon BE, Zhao M, et al. Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, D-dopachrome tautomerase. J Immunol 2008;181(4):2330- 2337